AIP
NPCE icon

Ameritas Investment Partners’s Neuropace NPCE Stock Holding History

Ameritas Investment Partners’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.3K Hold
2,455
– – ﹤0.01% 2353
2025
Q4 		$37.9K Hold
2,455
– – ﹤0.01% 2311
2025
Q3 		$25.3K Hold
2,455
– – ﹤0.01% 2559
2025
Q2 		$27.3K Buy
2,455
+1,118
+84% +$14K ﹤0.01% 2519
2025
Q1 		$16.4K Hold
1,337
– – ﹤0.01% 2637
2024
Q4 		$15K Hold
1,337
– – ﹤0.01% 2755
2024
Q3 		$9.32K Hold
1,337
– – ﹤0.01% 2943
2024
Q2 		$10.1K Buy
+1,337
New +$13.5K ﹤0.01% 2926
2022
Q2 		– Sell
-546
Closed -$4K – 3180
2022
Q1 		$4K Hold
546
– – ﹤0.01% 3000
2021
Q4 		$6K Hold
546
– – ﹤0.01% 3017
2021
Q3 		$9K Hold
546
– – ﹤0.01% 2967
2021
Q2 		$13K Buy
+546
New +$12.7K ﹤0.01% 2892

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ameritas Investment Partners's NPCE Position: Q1 2026 in Review

Ameritas Investment Partners held its Neuropace (NPCE) position steady in Q1 2026 at 2,455 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Ameritas Investment Partners first reported a position in NPCE in Q2 2021 and has held it in 12 quarters since. The position peaked at $37.9K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Ameritas Investment Partners held 2,455 shares of Neuropace worth $32.3K as of Q1 2026.
  • Ameritas Investment Partners left its Neuropace share count unchanged in Q1 2026.
  • Neuropace made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2353 holding.
  • Ameritas Investment Partners first reported a position in Neuropace in Q2 2021 and has held it in 12 quarters since.
  • Ameritas Investment Partners's Neuropace position peaked at $37.9K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.